Company intelligence / Profile preview
Boan Biotech
Yantai, Shandong Province, Chinaboan-bio.com ↗
- Ownership
- Private
- Employees
- ~777
- Development stage
- Other
01
Overview
Boan Biotech has three commercialized biologics in China covering oncology and metabolic disease. Its pipeline includes at least six late-stage assets expected to reach commercialization soon—including dulaglutide and aflibercept biosimilars under regulatory review—and more than ten innovative biologics spanning oncology, autoimmune disease, ophthalmology, metabolism, and advanced cell therapy. The company leverages four major technology platforms across the full biopharma value chain from discovery through manufacturing.
- Therapeutic areas
- Metabolic DisordersOncologyOphthalmologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesAntibody-drug conjugates (ADCs)Cell therapies (CAR-T)
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Beyond the preview
Go deeper on Boan Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boan Biotech.